the importance of a guaranteed minimal intake in milliliters in the first days of life. However, to date we have not communicated any preference regarding formula milk versus mother's milk obtained after breast pumping.
In the Dutch population NBS program in 2013, only 62% of the positive neonates were referred to a metabolic physician before day 8. Therefore, our protocol includes analysis of dried blood-spot acylcarnitines before NBS test results can become available. Usually, the dried blood spots are delivered to our center by family members on the second day of life and the results of the acylcarnitine analysis are reported the same day. Although not formally studied, parents reported to us that the protocol substantially reduces the stress regarding the diagnosis and feeding regimen while they await the results of the national NBS program. Table 2 presents acylcarnitine concentrations in umbilical cord blood and the first days of life of two (c.985A>G ACADM homozygote) MCAD-deficient neonates from families in which the index patients were previously identified by the NBS program. These results illustrate that cord-blood acylcarnitines may enable rapid biochemical diagnosis of these newborns. In our (still relatively limited) experience, neonates in whom MCAD deficiency was excluded have normal (ratios of) acylcarnitines in umbilical cord blood.
Walter et al. studied the overall feasibility of acylcarnitine and amino acid analysis via tandem mass spectrometry in umbilical cord blood for the identification of inherited metabolic diseases. 3 The authors mentioned several limitations of umbilical cord blood metabolite screening. First, depending on the nature of the metabolic defect and the role of enteral feeding and fasting, only a few inherited metabolic diseases can be detected. 3 However, the feasibility of more rapid identification also depends on the nature of the disorder. Walter et al. used cutoff values only for acylcarnitine concentrations, but using their molar ratios as well might increase the detection rate of some disorders. 3 Despite reports of agerelated variations in acylcarnitine concentrations comparing umbilical cord blood samples with NBS samples, 4,5 dried cord blood-spot acylcarnitine reference values for concentrations including their molar ratios are not yet available. Second, theoretically umbilical blood acylcarnitines can be influenced by maternal (nutritional and/or disease) status. 3 This problem can be circumvented by sequential acylcarnitine (ratio) analysis. Therefore, in addition to the regular NBS program, acylcarnitine concentrations in umbilical cord blood may provide an early indication.
The abnormal umbilical cord blood acylcarnitine profiles in MCAD-deficient neonates may indicate the importance of mitochondrial fatty-acid oxidation prenatally and/or during the perinatal transition. This period is characterized by important changes in cardiac energy metabolism (i.e., from predominantly carbohydrate-driven toward mitochondrial fatty 
